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REVIEW
Abstract: Calcium channel blockers (CCBs) are a widely used group of antihypertensive
agents. CCBs are efficacious in the reduction of blood pressure but the extent to which they
manifest beneficial effects on cardiovascular disease is variable. Clinical studies indicate that
pleiotropic actions make significant contributions to the efficacy of agents aimed at preventing
atherosclerosis. The “response to retention” hypothesis implicates the binding and retention
of lipoproteins by glycosaminoglycan chains on proteoglycans as an initiating step in
atherogenesis. Atherogenic factors act as agonists and several classes of drugs including
peroxisome proliferating-activated receptor (PPAR)-α and -γ ligands act as antagonists in this
model. Initial data have demonstrated that high concentrations of CCBs inhibit proteoglycan
synthesis. Newer preliminary data show that the action is very modest at reasonable
concentrations and appears to be independent of calcium channel blocking activity. We have
reviewed the role of cardiovascular drugs acting on vascular smooth muscle proteoglycan
synthesis and considered the potential action of CCBs in this model. We conclude that the
inhibition of proteoglycan synthesis by CCBs does not play a role in the attenuation of
atherosclerosis; however, the antihypertensive efficacy and alternative beneficial actions provide
support for the use of CCBs in the therapy of cardiovascular disease.
Keywords: atherosclerosis, calcium channel blockers, cardiovascular disease, lipoprotein,
proteoglycans
Introduction
Calcium channel blockers (CCBs) are efficacious and widely used drugs in the
treatment of hypertension as a risk factor for cardiovascular disease (Hernandez et al
2003). They are chemically a heterogenous group of agents comprising three distinct
classes: phenylalkylamines, dihydropyridines, and benzothiazepines (Fleckenstein
1990). CCBs are a group of agents used therapeutically in cardiovascular disease
due to their hypotensive action. This hypotensive action is through the vasodilatation
of blood vessels, which occurs via the antagonism of calcium entry on vascular
smooth muscle cells (Antman et al 1980). CCBs classically block depolarization-
mediated contraction of blood vessels in vitro at very low (nmol/L) concentrations,
and this action is extended in vivo where they exhibit efficacious antihypertensive
activity. At higher (µmol/L) concentrations, CCBs block vasoactive agonist induced
increases in cellular calcium, although the contribution of this action to in vivo efficacy
is unclear (Kohrogi et al 1985).
Hypertension is a driver of the development of atherosclerosis underlying
cardiovascular disease, although the molecular mechanisms and associations have
not been resolved (MacMahon et al 1990). Elevated blood pressure is a potent
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accelerating factor in cardiovascular disease and this is
particularly so in the presence of diabetes (Lehto et al 1997).
In the UK Prospective Diabetes Study (UKPDS), tight blood
pressure control in patients with diabetes was more effective
than improving hyperglycemia in reducing cardiovascular
disease (UKDPS 1998a, 1998b).
Current therapeutic interventions for the prevention of
cardiovascular disease are directed at the established risk
factors such as hypertension, dyslipidemia (elevated low-
density lipoprotein [LDL]-cholesterol and triglycerides and
decreased high-density lipoprotein [HDL]-cholesterol), and
hyperglycemia. The most recent classes of agents for the
treatment of these risk factors, such as angiotensin-
converting enzyme (ACE) inhibitors for the treatment of
high blood pressure (UKDPS 1998b; Jensen 2000), statins
for hypercholesterolemia (Bellosta et al 1998), and
glitazones for hyperglycemia (Sidhu et al 2004) have
demonstrated direct beneficial vascular effects that have
been termed “pleiotropic” actions. These pleiotropic actions
occurring directly in blood vessels are broadly vaso-
protective or “antiinflammatory” and contribute significantly
to the primary action on the target risk factor to alleviate
the development of atherosclerosis and cardiovascular
disease. While the primary action of CCBs is to reduce blood
pressure via L-type calcium channel blockade, the role and
contribution of direct antiatherogenic actions to the
cardiovascular protection offered by this class of drug is
unresolved.
Our knowledge of the factors involved in atherogenesis
and development of life-threatening unstable atherosclerotic
plaques has increased considerably in recent years and now
extends well beyond the notion of “endothelial dysfunction”
(Libby 2002). It is widely accepted that atherosclerosis
commences with the retention, accumulation, and
modification of lipids in the vessel wall. This process occurs
due to the “trapping” role of highly negatively charged
proteoglycans, utilizing ionic interactions to bind and retain
positively charged amino acid residues on the apolipoprotein
(Apo) moiety of an LDL particle. This retention of LDL
within the vessel wall leads to the presentation of
lipoproteins for metabolic alterations (Williams and Tabas
1995, 1998). Apolipoproteins bind to the glycosaminoglycan
(GAG) chains on proteoglycans (Ballinger et al 2004;
Tannock et al 2004). GAG chains on vascular proteoglycans
are subject to pharmacological and possibly therapeutic
modulation in a manner that may be pro- and antiatherogenic
(Gustafsson and Boren 2004). Vasoactive hormones and
growth factors modulate the properties of the GAG chains
so that they bind more avidly to LDL (Figueroa and
Vijayagopal 2002; Little et al 2002). Proteoglycan:LDL
binding may be attenuated by a variety of pharmacological
and metabolic agents (Little et al 2002; Tannock et al 2002,
2004; Nigro et al 2004). Thus, we have considered the role
of CCBs in the regulation of proteoglycan biosynthesis in
vascular smooth muscle and provide some preliminary data
that impact on the possible mechanism of action of these
agents. This review addresses the antiatherogenic actions
of CCBs and considers whether or not antiatherogenic
effects of CCBs relate to proteoglycan metabolism in the
vasculature and if these actions are related to calcium
channel blockade.
Clinical trial data on the
regression or prevention of
atherosclerosis by CCBs
CCBs have demonstrated antiatherogenic properties in
various clinical studies, revealing slowed progression and
decreased formation of new lesions in treated patients
(Lichtlen et al 1990; Waters et al 1990; Hernandez et al
2003).
The International Nifedipine Trial on Anti-athero-
sclerotic Therapy (INTACT) study and its 6-year follow-up
demonstrated an appreciable and statistically significant
reduction of 28% in angiographically detected new coronary
lesions in coronary heart disease (CHD) patients treated with
nifedipine after a three-year interval. In the second three-
year period (from the second angiogram to the third one) a
further reduction of new lesions was found (78% in the
nifedipine group and 73% in the former placebo group)
(Lichtlen et al 1990).
The three-year Prospective Randomized Evaluation of
the Vascular Effect of Norvasc Trial (PREVENT) of 825
patients examined the effect of amlodipine on the
progression of atherosclerosis. Amlodipine therapy was
associated with a significant slowing of the progression of
carotid artery atherosclerosis (p = 0.007) (Pitt et al 2000;
Hernandez et al 2003). The Verapamil in Hypertension and
Atherosclerosis Study (VHAS) showed that verapamil
caused the regression of thicker carotid lesions in parallel
with a reduction in the incidence of cardiovascular events
(Zanchetti et al 1998).
In the Regression Growth Evaluation Statin Study
(REGRESS), co-administration of the CCBs amlodipine orVascular Health and Risk Management 2005:1(3) 201
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nifedipine with pravastatin resulted in a significant reduction
in the appearance of new angiographic lesions (p = 0.0078)
(Jukema et al 1996). In two subprotocols of the Intervention
as a Goal in the Hypertension Treatment (INSIGHT) study,
nifedipine treatment prevented an increase in intima-media
thickness in the carotid artery and significantly (p < 0.05)
slowed the progression of coronary calcification compared
with the diuretic co-amilozide in hypertensive patients
(Motro and Shemesh 2001; Simon et al 2001). In another
subprotocol of the INSIGHT study, nifedipine was shown
to be as effective as co-amilozide in reducing cardiovascular
complications in patients with hypertension and diabetes;
however, treatment with nifedipine was associated with a
lower incidence of vascular and non-vascular deaths and
new cases of type 2 diabetes mellitus (Mancia et al 2003).
Preliminary results of the European Lacidipine Study on
Atherosclerosis (ELSA) showed that the CCB lacidipine was
more effective in reducing the intima-media thickness
progression rate, compared with the β-blocker atenolol
(Zanchetti et al 2004).
Important information on the relationship between blood
pressure and vascular complications in people with diabetes
has been derived from the UKPDS (1998b). This large study
included calcium antagonists as add-on therapy to achieve
targets after the use of ACE inhibitors and β-blockers. The
original study demonstrated the efficacy of reducing blood
pressure in reducing complications in people with type 2
diabetes, especially microvascular complications (UKPDS
1998b). Further analysis demonstrated that there is a direct
relationship between blood pressure and complications in
people with diabetes and, importantly, that there is no
apparent threshold (Adler et al 2000). The study allowed
for a conclusion that the effects of ACE inhibitors and
β-blockers exceeded those predicted from their blood
pressure lowering action and thus gave further evidence of
the potential role of pleiotropic actions in generating the
best outcome in patients with cardiovascular risk factors
(Adler et al 2000).
Although there is evidence that CCBs reduce blood
pressure and can inhibit the development and progression
of atherosclerotic lesions in patients with cardiovascular risk
factors, the mechanisms by which these effects occur
remains questionable. That is, do the antiatherogenic effects
of CCBs include an action on calcium channels, and do the
actions extend beyond the reduction in blood pressure
associated with CCB therapy?
Cellular mechanisms of
atherosclerosis
The primary initiating factor in plaque formation is the
retention and accumulation of low-density lipoproteins in
the subendothelial matrix of a blood vessel (Skalen et al
2002). LDL is transported through the endothelium by small
vesicular carriers, a process of transcytosis that is
nonsaturable and augmented at high concentrations of LDL
(Vasile et al 1983). The accumulation and retention of LDL
within the vessel wall involves an interaction between the
ApoB protein moiety of the LDL particle and matrix
proteoglycans, synthesized by vascular smooth muscle cells
(Lusis 2000). Native LDL is not phagocytozed by
macrophages, therefore trapped LDL undergoes a process
of modification including lipolysis, proteolysis, oxidation,
aggregation, and glycation in the presence of hyperglycemia,
before being taken up to form foam cells via scavenger
receptors on these cells and smooth muscle cells (Kadar
and Glasz 2001). Oxidized LDL is also chemoattractive to
circulating monocytes, attracting monocytes to the vessel
wall where they penetrate and differentiate into
macrophages. The accumulation of oxidized LDL stimulates
the overlying endothelial cells to secrete proinflammatory
molecules such as monocyte chemoattractant protein
(MCP-1) and macrophage colony stimulating factor
(M-CSF) as well as adhesion molecules ICAM-1, P selectin,
and E selectin, which leads to the recruitment of more
monocytes and cells of the immune system (T cells) into
the vascular wall. Thus, vascular proteoglycans that trap
and retain atherogenic LDL particles have an initiating role
in atherogenesis (Skalen et al 2002; Ballinger et al 2004).
Advanced atherosclerotic plaques consist of two main
components: soft, lipid-rich atheromatous material and hard,
collagen-rich sclerotic tissue (Yutani et al 1999). Hard,
fibrous plaques are characterized by a growing mass of
extracellular lipid and the accumulation of smooth muscle
cells (SMCs). SMCs secrete an extracellular matrix which
leads to the formation of a fibrous cap (Lusis 2000). The
cap protects the deeper components of the plaque from
contact with circulating blood (Shah 2003). Atherosclerotic
lesions also contain significant amounts of collagen, which
confers firmness and stability on the plaque. The stability
of a plaque is also influenced by the amount of intimal
calcification (Shanahan et al 1994). Unstable or “vulnerable”
plaques have an eccentric, lipid-rich core with a thin
overlying fibrous cap. The lipid core may confer a
mechanical disadvantage to the plaque, as it redistributesVascular Health and Risk Management 2005:1(3) 202
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stress to the shoulder regions of the plaque, which in nearly
60% of cases is the area at which the fibrous caps rupture
(Shah 2003). Increased numbers of inflammatory cells and
an increased expression of inflammatory mediators are
observed at sites of plaque rupture (Lutgens et al 2003).
Vulnerable plaques may produce less luminal stenosis due
to outward remodeling. Once the atheromatous “gruel”
comes into contact with blood from the lumen of the artery,
there is activation of the clotting cascade and platelet
activation, adhesion, and aggregation, leading to thrombosis,
vessel occlusion, ischemia, vascular and myocardial cell
death, and tissue necrosis (Shah 2003). This process has
important implications for coronary and cerebral arterial
occlusion as myocardial infarction and stroke will occur if
a significant portion of the heart and brain tissue is affected.
Modulation of GAG synthesis as an
initiating factor in atherosclerosis
The entrapment of lipoproteins in the vessel wall by matrix
molecules, most prominently proteoglycans, is continuing
to emerge as a critical step in atherogenesis (Williams and
Tabas 1995; Skalen et al 2002). This phenomenon forms
the basis of the “response-to-retention” hypothesis
explaining the origin of atherosclerosis (Williams and Tabas
1995). The interaction of proteoglycans and lipoproteins
sets the stage and is responsible for predisposing the arterial
intima to the development of atherosclerotic cardiovascular
disease (Chait and Wight 2000).
Mogen Faber first suggested the involvement of
proteoglycans in the retention of LDL in the vessel wall in
1949 (Faber 1949). Arterial proteoglycans participate in
adhesion, migration, and proliferation, important processes
in homeostasis and lipid metabolism leading to athero-
genesis. Therefore, any changes to proteoglycan structure,
content, or concentration, could affect the behavior of
vascular cells and the pathophysiological properties of blood
vessels. Increased production of arterial wall proteoglycans
is implicated in atherogenesis (Tao et al 1997). Injury to the
arterial wall results in an increase in the production of
proteoglycan variants that have enhanced binding to LDL
(Srinivasan et al 1993). A number of studies have
demonstrated that increasing the number of negatively
charged residues on the GAG chain, by either an increase
in proteoglycan synthesis or change in the length,
composition, and sulfation pattern of the GAGs during
atherogenesis leads to increased retention of atherogenic
LDL in the vessel wall (Radhakrishnamurthy et al 1990;
Williams and Tabas 1995, 1998; Hurt-Camejo et al 1997;
Camejo et al 1998; Chait and Wight 2000; Little et al 2002).
Thus, pharmacological and potentially therapeutic
modulation of GAG synthesis on vascular proteoglycans is
emerging as a potential pathway for the recognition of the
beneficial “pleiotropic” actions of existing agents and
potentially a source of new mechanistic agents for the
prevention of atherosclerosis (Nigro et al 2005). Several
important drug classes including CCBs are known to
modulate proteoglycan synthesis in vascular smooth muscle
(Schonherr et al 1997; Vijayagopal and Subramaniam 2001;
Nigro et al 2004).
Pro- and antiatherogenic factors
affecting proteoglycan biosynthesis
and structure in vascular smooth
muscle
Our extension of the response to retention hypothesis is that
growth factors that modify the properties of the GAG chains
on vascular proteoglycans, such that they bind more avidly
to LDL, will be proatherogenic (Ballinger et al 2004). It
follows that agents that can antagonize growth factor induced
GAG chain modification would reduce GAG chain affinity
for LDL and thus would be antiatherogenic. These
interactions can and have been studied in vitro, and the
validity of these observations depends upon the outcomes
available from tightly controlled studies in animal models
and from clinical trial data.
Agents that have been shown to modify the biosynthesis
and structure of the GAG chains on proteoglycans produced
by vascular smooth muscle include the growth factors
platelet derived growth factor and transforming growth
factor (TGF)-β (Schonherr et al 1991; Little et al 2002),
vasoactive agents such as angiotensin II (Shimizu-Hirota et
al 2001; Figueroa and Vijayagopal 2002), and metabolic
agents such as free fatty acids (Olsson et al 1999) and
oxidized LDL (Chang et al 2000). The most common
alteration is an increase in the size of the proteoglycans,
which occurs by an increase in the length of the GAG chains
with no change in the proteoglycan core protein (Nigro et
al 2004). Agonist-induced changes in the size of the
proteoglycans have been demonstrated by decreased
mobility on SDS-PAGE (sodium dodecyl sulfate-
polyacrylamide gel electrophoresis) and, more importantly,
by earlier elution using size exclusion chromatography
techniques. Changes in the sulfation pattern and the
carbohydrate composition of the GAG chains couldVascular Health and Risk Management 2005:1(3) 203
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theoretically be associated with increased LDL binding, but
these have not been comprehensively described (Ballinger
et al 2004). Proteoglycans showed enhanced ionic properties
when examined by salt gradient elution from anion exchange
columns resulting in increased proteoglycan binding to LDL.
In vitro proteoglycan binding to LDL has been demonstrated
by both LDL affinity columns and Gel Mobility Shift Assays
(Ballinger et al 2004).
The actions of agonists on proteoglycan synthesis can
be blocked by several pharmacological and therapeutic
agents as well as by experimental agents that block signaling
pathways. Peroxisome proliferator-activated receptor
(PPAR) ligands have been extensively investigated for their
ability to modify proteoglycan synthesis in vascular smooth
muscle (Nigro et al 2002, 2004; Tannock et al 2004). Both
of the clinically relevant PPAR-α ligands, gemfibrozil and
fenofibrate, modify the structure of vascular proteoglycans
by inhibition of GAG chain elongation and alteration of
disaccharide composition, resulting in reduced binding to
human LDL in vitro (Nigro et al 2002, 2004). Thiazo-
lidinediones, the newest class of antidiabetic agents, which
are PPAR-γ ligands and insulin sensitizers, also inhibit the
synthesis and shorten the GAG chains on proteoglycans
synthesized by primate aortic SMCs, with a consequential
reduction in the binding affinity of proteoglycans to LDL
(Tannock et al 2004). The only published exception to the
paradigm of decreased GAG size and reduced binding to
LDL occurs in the instance of the 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase
inhibitors, the statins. Simvastatin and cerivastatin increase
the size of GAGs but decrease LDL binding and this
observation requires further investigation (Meyers et al
2003).
Much of the in vitro data cited above are supported by
studies in animal models. Fenofibrate treatment of ApoE
knock out (KO) mice reduces lipid loading in the vessel
wall and the size of the atherosclerotic lesions (Duez et al
2002). Troglitazone treatment of LDL receptor KO mice or
ApoE KO mice also markedly reduces the area of lipid
lesions in the aorta of mice fed high-fat diets (Chen et al
2001; Collins et al 2001). Similarly, treatment of LDL
receptor KO mice or ApoE KO mice with rosiglitazone
showed a 30% and 18% reduction in aortic lesion area,
respectively (Li et al 2000; Claudel et al 2001). Thus, the
in vitro actions of agents are paralleled by observations in
animal models of atherosclerosis but it has not been
demonstrated that the alterations of proteoglycans occur
in vivo and actually cause the reduced lipid binding and
deposition in the vessel wall.
Antiatherogenic actions of CCBs
based on inhibition of
proteoglycan synthesis
CCBs have been reported to inhibit proteoglycan synthesis
in human aortic SMCs (Vijayagopal and Subramaniam
2001) and in other cell types (Fagnen et al 1999), with a
related reduction in proteoglycan size. Cultured human
aortic SMC proteoglycan synthesis is inhibited by
amlodipine and nifedipine with concentrations that are very
high (up to 35 µmol/L amlodipine and 58 µmol/L nifedipine)
compared with relevant therapeutic levels (Vijayagopal and
Subramaniam 2001). In addition, treatment of aortic SMCs
with amlodipine resulted in qualitative changes in the newly
synthesized proteoglycans, which included reduced
molecular size, decreased charge density, and reduced
binding to LDL (Vijayagopal and Subramaniam 2001). The
proteoglycans synthesized by SMCs in the presence of
amlodipine bind LDL with a much lower affinity
(Vijayagopal and Subramaniam 2001). Large effects on LDL
binding affinity of proteoglycans after treatment with
amlodipine may be due to the changes in the extent of
sulfation (ionic charge) and size and number of GAG chains
(Vijayagopal and Subramaniam 2001). These studies
concluded that CCBs might be involved in proteoglycan
biosynthesis presumably by modulating intracellular
calcium ion levels. It is thus important to identify the precise
mechanisms of how CCBs manifest their actions on
proteoglycan synthesis.
Mechanism of action of CCBs on
vascular proteoglycans: does the
effect of calcium antagonists on
proteoglycans involve calcium
channel blockade?
It has been implied that the mechanism of action of CCBs
on vascular proteoglycan synthesis involves calcium channel
blockade (Vijayagopal and Subramaniam 2001). We have
recently extended these studies with amlodipine by
examining the actions of the stereoisomers of amlodipine
on proteoglycan synthesis in human vascular smooth
muscle. The (S-)-amlodipine enantiomer is a more active
CCB than (R+)-amlodipine (Arrowsmith et al 1986;
Goldmann et al 1992; Luksa et al 1997). Due to theVascular Health and Risk Management 2005:1(3) 204
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difference in stereo-orientation of the amplodipine isomers
and thus activity at calcium channels, it is expected that if
the effects on proteoglycans occurred via calcium channel
blockade activity, only the (S-)-amlodipine enantiomer
would have inhibitory effects on proteoglycan synthesis.
We examined the activity of the amlodipine stereoisomers
against basal proteoglycan biosynthesis and synthesis
stimulated by the calcium-dependent and calcium-
independent vasoactive agents endothelin-1 and TGF-β,
respectively. Both enantiomers of amlodipine resulted in
similar concentration-dependent inhibitory effects on
35S-SO4 incorporation into proteoglycans (Figure 1, left
panel). We also examined the effect on proteoglycan size as
a surrogate for GAG size and the effects were identical for
both amlodipine isomers (Figure 1). It should be noted that
the concentration of amlodipine used in these experiments
was considerably lower than the concentration used by
Vijayagopal group (Vijayagopal and Subramaniam 2001).
A lower concentration was used because in an earlier study
of ours on related calcium blockers (Agrotis et al 1993) and
in the present experiments, we observed toxicity when CCBs
were used at concentrations above 10 µmol/L, which was
manifest as cell detachment from the underlying matrix.
The role of intracellular calcium
on proteoglycan synthesis
The calcium ion itself is an important second messenger
for signaling events. Inositol (1,4,5) triphosphate produced
from the enzymatic cleavage of phosphatidylinositol-
bisphopshate by phopsholipase C, stimulates the release of
calcium from intracellular stores. Calcium is able to activate
a range of intracellular mediators, including protein kinase
C (Guillon et al 1987). Therefore, we examined the potential
involvement of calcium ions in proteoglycan biosynthesis.
Ionomycin, an ionophore that raises the concentration of
intracellular calcium, was used (Perlman et al 1980). It was
found that raising the intracellular calcium concentration
had no effect on the incorporation of sulfate into proteo-
glycans. An SDS-PAGE of these samples demonstrated that
Figure 1 Stereoisomers of the CCB amlodipine with or without CCB activity have equivalent effects on proteoglycan synthesis in human VSMCs. Human VSMCs
were treated with (S-)-amlodipine (1–10 µmol/L, CCB inhibitor) and (R+)-amlodipine (1–10 µmol/L, no CCB activity) in the presence of TGF-β1 (top) and endothelin-
1 (ET-1, bottom) and metabolically labeled with [35S]-SO4 for 24 h. Proteoglycans were quantitated by the CPC precipitation assay (left) and assessed by SDS-PAGE
(right) as described previously (Nigro et al 2002). Abbreviations: CCB, calcium channel blockers; CPC, cetylpyridinium chloride; SDS-PAGE, sodium dodecyl sulfate-
polyacrylamide gel electrophoresis; TGF, transforming growth factor; VSMCs, vascular smooth muscle cells.Vascular Health and Risk Management 2005:1(3) 205
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ionomycin had no effect on the electrophoretic mobilities
of the proteoglycan bands, and hence no effect on their sizes
(Figure 2).
Bis (2-aminophenyl)ethyleneglycol-N,N,N´,N´-
tetraacetic acid, tetraacetoxymethyl ester (BAPTA-AM) is
a chelator of calcium ions and prevents a rise in intracellular
calcium concentration by acting as a calcium buffer (Tsien
1980). BAPTA-AM (10 µmol/L) had a significant effect on
basal sulfate incorporation into proteoglycans, and had a
significant effect to decrease sulfate incorporation stimulated
by both TGF-β and endothelin-1; however, the effect of
BAPTA-AM on the agonist stimulated sulfate incorporation
was of a similar degree to the effect of BAPTA on basal
sulfate incorporation. Thus, we conclude that effects seen
on agonist stimulated sulfate incorporation were due to the
effect of BAPTA-AM on basal sulfate incorporation.
Conclusions
Drugs for the prevention of cardiovascular disease currently
target risk factors of blood pressure, lipid abnormalities,
and hyperglycemia in people with diabetes. Clinical studies
have shown the therapeutic agents that show the greatest
efficacy in treating and preventing cardiovascular disease
are those that have complementary, so called, pleiotropic
actions directly on blood vessels to prevent some of the many
pathways involved in the formation of atherosclerotic
plaques (Barbier et al 2002). Current research in the area of
the pathobiology of atherosclerotic plaque formation is
likely to lead to mechanistic agents that directly target the
blood vessel wall to prevent the development of or increase
the stability of plaques (Staels 2002). In time, the
combination of agents targeting risk factors with mechanistic
agents targeting the vessel wall should reduce the resistant
Figure 2 Intracellular calcium does not play a role in VSMC proteoglycan synthesis. Human VSMCs were treated with ionomycin (0.01–10 nmol/L, which increases
intracellular calcium, upper panels) or BAPTA-AM (1–10 µmol/L, a calcium chelator, lower panels) in the presence of TGF-β1 and ET-1 and metabolically labeled with
[35S]-SO4 for 24 h. Proteoglycans were quantitated by the CPC precipitation assay (left) and assessed by SDS-PAGE (right) as described previously (Nigro et al 2002).
Abbreviations: CPC, cetylpyridinium chloride; ET-1, endothelin-1; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; TGF, transforming growth
factor; VSMC, vascular smooth muscle cell.Vascular Health and Risk Management 2005:1(3) 206
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or residual disease which remains apparent in most clinical
trials.
Perspective
CCBs remain a most interesting class of drug. These agents
are efficacious in most situations for the lowering of blood
pressure. Whether or not this translates to the extent of the
blood pressure lowering or beyond to a reduction in
atherosclerotic cardiovascular disease is unresolved.
The response to retention hypothesis of atherogenesis
based on the binding and retention in the vessel wall of
atherogenic lipoproteins by GAG chains of proteoglycans
is emerging as a robust model in cell and animal studies.
We have considered the action of CCBs from the perspective
of their actions on vascular proteoglycans. Initial data have
shown some potentially antiatherogenic actions that
occurred at very high (> 30 µmol/L) concentrations and
which were ascribed to an action of calcium channels. We
have offered some preliminary data that directly extend those
studies using stereoisomers of amlodipine, which have
different affinities for calcium channels. We found that at
more modest concentrations (≤ 10 µmol/L), amlodipine has
very small effects on proteoglycan synthesis and the
stereoisomers have identical actions suggesting that the
inhibitory action is not targeted at or dependent upon an
action on calcium channels. This may not be surprising in
that there are few theoretical possibilities for a relationship
between calcium channel activity and antiatherosclerotic
actions perhaps other than via intracellular calcium.
A well controlled study in ApoE KO mice induced with
diabetes showed that an ACE inhibitor (irbesartan) and CCB
(amlodipine) both reduced blood pressure but only the ACE
inhibitor was associated with a reduction in atherosclerotic
lesion formation (Candido et al 2004). Accordingly, from
our in vitro and in vivo data like that of Candido et al (2004),
we speculate that CCBs do not have an efficacious action
on proteoglycan synthesis in vascular smooth muscle that
makes any meaningful contribution to the prevention of
atherosclerosis.
CCBs may have a role as a primary or, perhaps more
importantly, as an adjunct therapy for the reduction in blood
pressure because hypertension is clearly one of the most
prominent drivers of atherosclerosis. Hypertension is widely
recognized as being undertreated in general practice (Gaede
et al 2003) and in patients for which CCBs are well tolerated
they may make an important contribution to the lowering
of blood pressure towards the desired target levels. Other
agents, some existing and having beneficial pleiotropic
actions to prevent atherosclerosis and some agents that
directly target mechanistic pathways of atherogenesis in the
vessel wall, remain the most important pathways for
targeting and preventing cardiovascular disease. The
widening occurrence of obesity and the epidemic of Type 2
diabetes are driving an increase in atherosclerotic
cardiovascular disease. New and efficacious agents and
strategies are required to complement lifestyle changes in
alleviating this wave of cardiovascular disease that threatens
the health budgets of many countries and the health and
longevity of individuals.
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